Figure 8 | Scientific Reports

Figure 8

From: In Vitro and In Vivo Characterization of PCC0104005, a Novel Modulator of Serotonin-Dopamine Activity, as an Atypical Antipsychotic Drug

Figure 8

The adverse reactions that may be caused by PCC0104005. Rats were administered vehicle alone, PCC0104005 (1.5, 3.0, or 6.0 mg/kg), aripiprazole (Ari, 1.5 mg/kg, i.g.) or risperidone (Ris, 0.2 mg/kg) for 28 days before testing. Results are presented as mean ± S.E.M. (n = 3–5). (A) Plasma prolactin levels in different groups. Plasma prolactin levels were assessed using a commercially available Prolactin ELISA Kit. *P < 0.05, **P < 0.01 drug delivery groups vs. the control group. (B,C) Plasma total cholesterol and triglyceride levels in different groups. (D) Weight changes in different groups. *P < 0.05, **P < 0.01 drug delivery groups vs. the control group.

Back to article page